Zobrazeno 1 - 10
of 387
pro vyhledávání: '"R Egbring"'
Publikováno v:
European Journal of Haematology. 38:231-240
The prognosis of septicaemia depends on the occurrence of complications such as shock and coagulation defects. The damage to haemostasis is usually explained by the action of the main coagulation and fibrinolysis enzymes, thrombin and plasmin. This p
Publikováno v:
Scandinavian Journal of Haematology. 27:253-262
Bleeding is a common complication in patients suffering from multiple myeloma. In some cases a defect in fibrin formation has been suggested as one possible cause of haemorrhagic tendency. As shown in this investigation the defect in fibrin formation
Publikováno v:
DMW - Deutsche Medizinische Wochenschrift. 114:939-944
The effect of fenofibrate (a clofibrate derivative) on fibrinogen concentration, blood viscosity and myocardial microcirculation was examined in 35 patients with coronary heart disease (n = 27) or hypertension (n = 8). After eight weeks' administrati
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis. 3:226-233
Henoch-Schoenlein purpura (HSP) is a generalized anaphylactoid "teucocytoclastic" vasculitis, which in more than 50% of patients is complicated by gastrointestinal symptoms such as vomiting, abdominal pain, melena and life-threatening bleedings. In f
Publikováno v:
Annals of Oncology. 8:781-784
There is evidence that activation of coagulation by influencing tumour biology may have impact on clinical course of lung cancer.We measured the activation markers thrombin-antithrombin complex (TAT) and prothrombin fragment F1 + 2 in 99 lung cancer
Publikováno v:
Transfusion Medicine and Hemotherapy. 24:348-353
Objective: Investigation of the role of factor XIII (FXIII) and FXIII substitution in Henoch-Schönlein purpura with severe gastrointestinal involvement in adult intensive care unit patients. Design: Prospective study. Setting: Medical intensive care
Publikováno v:
Seminars in Thrombosis and Hemostasis. 22:419-425
Congenital factor XIII deficiency is a rare disease, but has provided valuable information on the physiological role of factor XIII and the benefit of factor XIII replacement therapy. It could be shown that not only homozygous patients but also heter
Publikováno v:
Hämostaseologie. 16:174-179
ZusammenfassungAntikörper gegen FXIII sind extrem selten: Bisher wurden zwei Patienten mit angeborenem FXIII-Mangel und 21 vorher gerinnungsnormale Patienten beschrieben, die Hemmkörper gegen FXIII entwickelten. Häufigster Auslöser für erworbene
Publikováno v:
Blood. 86:989-1000
The fibrinogen structural variant, Marburg (A alpha 1–460B beta gamma)2, is comprised of normal B beta and gamma chains but contains severely truncated A alpha chains that are missing approximately one half of their factor XIIIa cross-linking domai